CO5570111A1 - NEW TECHNIQUE TO OBTAIN IN A SINGLE PHASE AUTOMOTIVE GROWTH, THROMBIN AND FIBRINE FACTORS, TO BE APPLIED IN GELIFIED FORM - Google Patents

NEW TECHNIQUE TO OBTAIN IN A SINGLE PHASE AUTOMOTIVE GROWTH, THROMBIN AND FIBRINE FACTORS, TO BE APPLIED IN GELIFIED FORM

Info

Publication number
CO5570111A1
CO5570111A1 CO05034788A CO05034788A CO5570111A1 CO 5570111 A1 CO5570111 A1 CO 5570111A1 CO 05034788 A CO05034788 A CO 05034788A CO 05034788 A CO05034788 A CO 05034788A CO 5570111 A1 CO5570111 A1 CO 5570111A1
Authority
CO
Colombia
Prior art keywords
autologous
concentrate
giving
factors
thrombin
Prior art date
Application number
CO05034788A
Other languages
Spanish (es)
Inventor
Elda Restrepo
Original Assignee
Elda Restrepo
Elda Restrepo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elda Restrepo, Elda Restrepo filed Critical Elda Restrepo
Priority to CO05034788A priority Critical patent/CO5570111A1/en
Publication of CO5570111A1 publication Critical patent/CO5570111A1/en

Links

Abstract

Caracterizado por ser un Procedimiento Autólogo de una sola Fase, con pequeños Volúmenes de Sangre. Caracterizado por obtenerse un Concentrado Autólogo de Factores de Crecimiento Tisular en Concentraciones Biológicamente Activas y Viables. Caracterizado por ser un Procedimiento Autólogo que obtiene altas concentraciones de Fibrinógeno, Trombina y Plaquetas. Caracterizado por ser un Procedimiento físico con un solo proceso de Centrifugación Estandarizado a 279,5 RCF por 10 minutos. Caracterizado por dar un Concentrado Autólogo Libre de Eritrocitos, Leucocitos y factores Pro inflamatorios. Caracterizado por dar un Concentrado Autólogo sin Riesgo Inmunogénico eliminando la posibilidad de Rechazo Inmunológico. Caracterizado por dar un Concentrado Autólogo sin Riesgo de Transmisión de Enfermedades Virales o Priónicas. Caracterizado por dar un Concentrado de Fibrina y factores de Crecimiento, que permite mantener la viabilidad de los Tejido aumentado la Vascularización y Oxigenación del mismo, descartando completamente el rechazo tisular en los injertos.Characterized by being a single phase autologous procedure, with small volumes of blood. Characterized by obtaining an Autologous Concentrate of Tissue Growth Factors in Biologically Active and Viable Concentrations. Characterized by being an Autologous Procedure that obtains high concentrations of Fibrinogen, Thrombin and Platelets. Characterized as a Physical Procedure with a single Standard Centrifugation process at 279.5 RCF for 10 minutes. Characterized by giving an Autologous Concentrate Free of Erythrocytes, Leukocytes and Pro inflammatory factors. Characterized by giving an Autologous Concentrate without Immunogenic Risk eliminating the possibility of Immune Rejection. Characterized by giving an Autologous Concentrate without Risk of Transmission of Viral or Prion Diseases. Characterized by giving a Fibrin Concentrate and Growth factors, which allows to maintain the viability of the tissue, increasing Vascularization and Oxygenation thereof, completely discarding tissue rejection in grafts.

CO05034788A 2005-04-13 2005-04-13 NEW TECHNIQUE TO OBTAIN IN A SINGLE PHASE AUTOMOTIVE GROWTH, THROMBIN AND FIBRINE FACTORS, TO BE APPLIED IN GELIFIED FORM CO5570111A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CO05034788A CO5570111A1 (en) 2005-04-13 2005-04-13 NEW TECHNIQUE TO OBTAIN IN A SINGLE PHASE AUTOMOTIVE GROWTH, THROMBIN AND FIBRINE FACTORS, TO BE APPLIED IN GELIFIED FORM

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CO05034788A CO5570111A1 (en) 2005-04-13 2005-04-13 NEW TECHNIQUE TO OBTAIN IN A SINGLE PHASE AUTOMOTIVE GROWTH, THROMBIN AND FIBRINE FACTORS, TO BE APPLIED IN GELIFIED FORM

Publications (1)

Publication Number Publication Date
CO5570111A1 true CO5570111A1 (en) 2005-10-31

Family

ID=40974237

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05034788A CO5570111A1 (en) 2005-04-13 2005-04-13 NEW TECHNIQUE TO OBTAIN IN A SINGLE PHASE AUTOMOTIVE GROWTH, THROMBIN AND FIBRINE FACTORS, TO BE APPLIED IN GELIFIED FORM

Country Status (1)

Country Link
CO (1) CO5570111A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011061561A2 (en) * 2009-11-19 2011-05-26 Elda Restrepo Method of obtaining regenerative molecular matrices and regenerative molecular matrices thus obtained

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011061561A2 (en) * 2009-11-19 2011-05-26 Elda Restrepo Method of obtaining regenerative molecular matrices and regenerative molecular matrices thus obtained
WO2011061561A3 (en) * 2009-11-19 2012-08-23 Elda Restrepo Method of obtaining regenerative molecular matrices and regenerative molecular matrices thus obtained

Similar Documents

Publication Publication Date Title
Ehrenfest et al. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF)
ES2832727T3 (en) Extracellular vesicles derived from human platelet lysate for use in medicine
Altaie et al. Use of platelet lysate for bone regeneration-are we ready for clinical translation?
Jager et al. Bone marrow concentrate: a novel strategy for bone defect treatment
Schallmoser et al. Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cells
Araki et al. Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: maximization of platelet concentration and removal of fibrinogen
Rubio-Azpeitia et al. Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience
Jonsdottir-Buch et al. Platelet lysates produced from expired platelet concentrates support growth and osteogenic differentiation of mesenchymal stem cells
ES2811085T7 (en) Compositions, uses, and preparation of platelet lysates
Blumberg et al. The platelet as an immune cell—CD40 ligand and transfusion immunomodulation
Chou et al. Autologous platelet concentrates in maxillofacial regenerative therapy
Naskou et al. Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells
PE20180817A1 (en) ABSORBING ARTICLE THAT HAS A HIGH CONTENT OF MATERIALS OF BIOLOGICAL ORIGIN
PE20071327A1 (en) JOINT CULTURE OF PLACENTARY STEM CELLS AND STEM CELLS FROM A SECOND SOURCE
Fernández-Medina et al. Systematic comparison of the effect of four clinical-grade platelet rich hemoderivatives on osteoblast behaviour
ATE395074T1 (en) AUTOLOGOUS THROMBIN
DK1856272T3 (en) Use of manufactured product and process for producing collagen solution and method for collagen separation of animal tissue
MX2019002288A (en) Cell suspension for use in the treatment of lower extremity peripheral artery disease.
ES2807897T3 (en) Stem cell therapy based on adipose stem cells
EP4292585A3 (en) Methods for isolating umbilical cord blood plasma products, tissue and cellular exosomes, and compositions and methods of use thereof
da Silva et al. Platelet-rich plasma lyophilization enables growth factor preservation and functionality when compared with fresh platelet-rich plasma
Zhang et al. Comparative study of different anticoagulants and coagulants in the evaluation of clinical application of platelet-rich plasma (PRP) standardization
JP7416786B2 (en) Method for preparing platelet release material
Narvaez-Flores et al. Cytotoxic and anti-inflammatory effects of chitosan and hemostatic gelatin in oral cell culture
GB2574333A (en) Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma

Legal Events

Date Code Title Description
FC Application refused
FG Application granted